tiprankstipranks
Advertisement
Advertisement
Arcturus Therapeutics price target lowered to $25 from $72 at Piper Sandler
PremiumThe FlyArcturus Therapeutics price target lowered to $25 from $72 at Piper Sandler
2M ago
Arcturus Therapeutics: Dose Selection and Trial Design Uncertainty Justify Neutral Rating Despite Modestly Higher Target Price
Premium
Ratings
Arcturus Therapeutics: Dose Selection and Trial Design Uncertainty Justify Neutral Rating Despite Modestly Higher Target Price
2M ago
Validating Arcturus’s mRNA Platform: Early Clinical Proof, Solid Cash, and Asymmetric Upside Support a Buy Rating
Premium
Ratings
Validating Arcturus’s mRNA Platform: Early Clinical Proof, Solid Cash, and Asymmetric Upside Support a Buy Rating
2M ago
Arcturus’ ARCT-2304 Flu Vaccine Trial Reaches Phase 1 Finish Line: What Investors Should Watch Next
PremiumCompany AnnouncementsArcturus’ ARCT-2304 Flu Vaccine Trial Reaches Phase 1 Finish Line: What Investors Should Watch Next
3M ago
Arcturus Therapeutics initiated with a Buy at Roth Capital
Premium
The Fly
Arcturus Therapeutics initiated with a Buy at Roth Capital
3M ago
Arcturus Therapeutics price target lowered to $7 from $9 at Citi
Premium
The Fly
Arcturus Therapeutics price target lowered to $7 from $9 at Citi
4M ago
Arcturus Therapeutics Earnings Call: Progress Amid Challenges
PremiumCompany AnnouncementsArcturus Therapeutics Earnings Call: Progress Amid Challenges
5M ago
Arcturus Therapeutics price target lowered to $72 from $140 at Piper Sandler
Premium
The Fly
Arcturus Therapeutics price target lowered to $72 from $140 at Piper Sandler
5M ago
Arcturus Therapeutics Reports Q3 2025 Financials and Pipeline Progress
Premium
Company Announcements
Arcturus Therapeutics Reports Q3 2025 Financials and Pipeline Progress
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100